NASDAQ · DXCM
DexCom, Inc.
$71.54 +$1.06 (+1.50%) 1D After hours
DexCom, Inc.
Key Metrics
$27.20B
Market cap
29.23×
P/E · TTM
$4.82B
Revenue · TTM
$930.40M
Net income
EPS · TTM
$2.28
Dividend yield
—
Free cash flow
$1.43B
Beta · 1Y
0.71
EBITDA · TTM
$1.46B
Gross margin
61.5%
Snapshot
Market cap$27.20B
Enterprise value—
Shares outstanding385.9M
52-wk range$54.11 – $89.98
Avg volume · 20D3.8M
Net cash
—
Book value / share$7.26
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About DexCom, Inc.
IPO dateApr 14, 2005
Employees11100
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E29.23
P/S5.64
P/FCF19.03
EV/EBITDA—
EV/Sales—
Graham №$19.31
Profitability
Gross
61.5%
Operating
25.0%
Net
19.3%
FCF
29.7%
ROE / ROIC
36.8% · 50.6%
Financial Health
Current ratio1.95
Quick ratio1.64
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$2.11B
Cash Flow · TTM
Operating CF
$1.78B
Capex
−$353.10M
Free cash flow
$1.43B
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
6 / 9
Middling fundamentals · 6 of 9 signals passing
Altman Z-Score
6.7
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
$19.31 vs $71.54
Trades 3.7× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings